Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough

被引:61
作者
Mainie, Inder [1 ]
Tutuian, Radu [1 ]
Castell, Donald O. [1 ]
机构
[1] Med Univ S Carolina, Div Gastroenterol & Hepatol, Charleston, SC 29425 USA
关键词
nocturnal acid; gastroesophageal reflux disease; H2 receptor antagonist; multichannel intraluminal impedance and pH;
D O I
10.1097/MCG.0b013e31814a4e5c
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The addition of a bedtime H2 receptor antagonist (H2RA) to proton pump inhibitor (PPI) b.i.d. to inhibit nocturnal acid breakthrough (NAB) is controversial. H2RA tolerance has been documented suggesting limitations in its effect. Aim: To compare the intragastric pH and NAB occurring with twice daily PPI with or without the addition of a H2RA. Method: Multichannel intraluminal impedance-pH studies in 100 patients were reviewed. Fifty-eight patients (female 41; mean age, 54 y; range, 17 to 8 5) were studied on twice daily PPI. Forty-two patients (female 36; mean age, 53 y; range 20 to 85) were studied on a PPI b.i.d. + H2RA for at least I month at bedtime. The percentage time of intragastric pH < 4 (upright, recumbent, and total) and NAB were compared between the groups. Results: In the patients with PPI b.i.d. 64% had NAB, compared with only 17% of patients on PPI b.i.d. and H2RA q.h.s. (P < 0.001). The percent time intragastric pH < 4 for patients on PPI b.i.d. was significantly higher (P<0.01) compared with patients on PPI b.i.d. + H2RA q.h.s. during upright (29.1 +/- 3.0 vs. 18.3 +/- 2.9), recumbent (33.5 +/- 3.4 vs. 12.5 +/- 3. 1), and entire period (31.5 +/- 2.8 vs. 18.0 +/- 3.0). Conclusions: The addition of a bedtime H2RA reduces the percentage time of the intragastric pH < 4 and also NAB. H2RA should be considered as adjunct therapy in whom greater suppression of gastric acid control is considered desirable.
引用
收藏
页码:676 / 679
页数:4
相关论文
共 20 条
[1]   APPROPRIATE ACID SUPPRESSION FOR THE MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE [J].
BELL, NJV ;
BURGET, D ;
HOWDEN, CW ;
WILKINSON, J ;
HUNT, RH .
DIGESTION, 1992, 51 :59-67
[2]  
CHIVERTON SG, 1992, ALIMENT PHARM THERAP, V6, P103
[3]   Review article: prevalence and epidemiology of gastro-oesophageal reflux disease [J].
Delaney, BC .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 :2-4
[4]   Overview of medical therapy for gastroesophageal reflux disease [J].
DeVault, KR .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1999, 28 (04) :831-+
[5]   Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough [J].
Fackler, WK ;
Ours, TM ;
Vaezi, MF ;
Richter, JE .
GASTROENTEROLOGY, 2002, 122 (03) :625-632
[6]   EPIDEMIOLOGY OF GASTROESOPHAGEAL REFLUX DISEASE [J].
HOWARD, PJ ;
HEADING, RC .
WORLD JOURNAL OF SURGERY, 1992, 16 (02) :288-293
[7]   The impact of gastroesophageal reflux disease on quality of life - Review of the literature [J].
Kamolz, T ;
Pointner, R ;
Velanovich, V .
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2003, 17 (08) :1193-1199
[8]  
Katz Philip O., 2000, American Journal of Medicine, V108, p170S
[9]  
Kuo B, 1996, AM J GASTROENTEROL, V91, P1532
[10]  
National Institute on Drug Abuse, 1999, NIH PUBL, V09-4180